'No evidence of disease activity' - is it an appropriate surrogate in multiple sclerosis?

ABSTRACT: The increasing number of disease-modifying treatments available for multiple sclerosis has broadened treatment options for patients, but also challenges clinicians to select the best therapy for each individual at the appropriate stage of the disease. Early prediction of treatment response still remains one of the main difficulties in the management of multiple sclerosis patients. The concept of 'no evidence of disease activity' (NEDA) has been proposed as a surrogate for treatment response based on the absence of relapses, disability progression and radiological activity. Although there are several apparently logical arguments for the NEDA approach, there are also some major concerns that have to be considered and that are not sufficiently addressed yet. Amongst others, each parameter's l

SUBMITTER: Hegen H 

PROVIDER: S-EPMC6099351 | biostudies-literature | 2018 Sep

REPOSITORIES: biostudies-literature